Tempus Developes Novel HLA-LOH Companion Diagnostic Test

Tempus developed a novel diagnostic test named the HLA-LOH assay, which is designed to serve as a companion diagnostic (CDx) test.

This test utilises a machine learning model to analyse sequence data generated by a next-generation sequencing-based xT CDx assay. HLA-LOH, biomarker, will potentially serve as an indicator of how cancer cells might respond to immune-based therapies.

HLA-LOH assay is to identify a specific molecular characteristic known as "allele-specific loss of heterozygosity" (LOH) within human leukocyte antigen (HLA) Class I alleles. This molecular distinction between cancerous and non-cancerous cells has significant implications, particularly in the context of immune therapy resistance.

The primary goal of this test is to measure the presence of this biomarker and thereby gain a better understanding of which patients might be more likely to respond positively to new therapeutic approaches.

The test is intended to be used for identifying cancer patients with solid tumours who could potentially benefit from targeted therapies, particularly when the patient's tumour has exhibited the allele-specific LOH for specific HLA Class I alleles.

The HLA-LOH assay is particularly valuable for using cell therapy against solid tumours. It also has wider applications in precision oncology when combined with established biomarkers. This test aims to detect HLA-LOH, potentially enhancing current therapies, and enabling the development of new treatments.